Related Experiment Video
Updated: May 12, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
Circulating miR-122 as a potential biomarker of liver disease
Omar F Laterza1, Mitchell G Scott, Philip W Garrett-Engele
1Merck Research Laboratories, Clinical Development Laboratory, Rahway, NJ, USA.
Aim:
Expression profiles indicate that miR-122 is specifically and abundantly expressed in liver. This study sought to determine miR-122 plasma concentrations in 15 apparently healthy subjects and 30 patients with liver disease, and clarify whether plasma miR-122 correlates with ALT.
Materials & Methods:
miR-122 was measured by quantitative PCR in healthy volunteers and patients with liver disease.
Results:
ALT was increased in two out of 15 (13%) apparently healthy subjects and 17 out of 30 (57%) liver disease patients. In healthy subjects, median miR-122 plasma concentration was 51.7 copies/20 pg RNA (range 16.0-312.0). In liver disease patients, median miR-122 was significantly elevated to 202.3 copies/20 pg RNA (range 20.9-1160.0; Mann-Whitney test between median concentrations; p = 0.0016).
Conclusion:
This small proof-of-principle study suggests that miR-122 may be a potential plasma biomarker of liver damage.
